When Ozempic Was Released: The Complete FDA Timeline, Patent Dates, and What Happened to Supply

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide 0.5 mg and 1 mg) received FDA approval on December 5, 2017, and launched commercially in January 2018 for type 2 diabetes treatment
• Wegovy (semaglutide 2.4 mg for weight loss) was approved June 4, 2021, creating a two-product semaglutide market with different indications
• Novo Nordisk's core semaglutide patents expire between 2031 and 2033, meaning generic versions won't be available until the early 2030s at the earliest
• The 2022-2024 shortage that put both products on the FDA shortage list triggered the compounded semaglutide market, which remains legal as of April 2026 under Section 503A pharmacy exemptions

Direct answer (40-60 words)

Ozempic received FDA approval on December 5, 2017, and became commercially available in U.S. pharmacies in January 2018. The medication was initially approved only for type 2 diabetes at 0.5 mg and 1 mg doses. The higher-dose formulation for weight loss (Wegovy, 2.4 mg) came later, approved June 4, 2021.

Table of contents

1. The official FDA approval and launch dates
2. What most articles get wrong about the "release" timeline
3. The clinical trial timeline that led to approval
4. Patent expiration dates and when generics become possible
5. The Wegovy approval and how it changed the semaglutide market
6. The 2022-2024 shortage: what happened and why it matters
7. How the shortage created the compounded semaglutide market
8. Current availability status as of April 2026
9. The regulatory difference between shortage-era compounding and post-shortage compounding
10. What happens when Novo Nordisk's patents expire
11. FAQ
12. Sources

The official FDA approval and launch dates

The FDA approved Ozempic (semaglutide injection) on December 5, 2017, under the New Drug Application (NDA) 209637. The approval covered two maintenance doses: 0.5 mg once weekly and 1 mg once weekly, both administered subcutaneously.

Commercial availability began in January 2018. The initial rollout was gradual. Novo Nordisk prioritized major pharmacy chains and specialty diabetes pharmacies first, then expanded to smaller independent pharmacies through February and March 2018.

The approved indication was narrow: "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." The FDA approval letter explicitly stated the drug was not indicated for weight loss and had not been studied for that purpose in the submitted trials.

The timeline matters because many patients and providers confuse the Ozempic approval date with the Wegovy approval date. These are different products with different NDAs, different dosing schedules, and different approved indications, even though both contain semaglutide as the active ingredient.

What most articles get wrong about the "release" timeline

The most common error in published content about Ozempic's release is conflating the FDA approval date with the date semaglutide became widely prescribed for weight loss. These events are separated by nearly four years.

Ozempic was approved in December 2017 for diabetes only. Off-label prescribing for weight loss began slowly in 2018 and 2019, accelerated in 2020 during the pandemic, and exploded in 2021 after the Wegovy approval created mainstream awareness of semaglutide's weight-loss efficacy.

The confusion stems from the fact that Wegovy and Ozempic contain the same active ingredient. Articles often describe "semaglutide's release" as a single event, when the regulatory reality is two separate approvals three and a half years apart.

The second common error is stating that Ozempic "became available" in 2022 or 2023. What happened in those years was a supply crisis and media attention, not a release. Ozempic had been on the market for four years by the time TikTok videos and celebrity coverage made it a household name.

The third error is claiming compounded semaglutide became legal after the shortage. Compounding under Section 503A has always been legal when a drug is in shortage. What changed in 2022 was not the law but the FDA's decision to add semaglutide to the shortage list, which triggered the exemption.

These distinctions matter for patients trying to understand whether their access to semaglutide is stable or subject to regulatory change. The approval date determines patent expiration. The shortage date determines compounding legality. The off-label prescribing timeline determines insurance coverage patterns.

The clinical trial timeline that led to approval

Ozempic's approval was based on the SUSTAIN clinical trial program, a series of eight Phase 3 trials enrolling more than 8,000 patients with type 2 diabetes between 2015 and 2017.

The phase 3 trials were:

Trial	N	Comparator	Primary endpoint	Result
SUSTAIN-1	388	Placebo	HbA1c reduction at 30 weeks	-1.45% (1 mg dose) vs -0.09% placebo
SUSTAIN-2	1,231	Sitagliptin 100 mg	HbA1c reduction at 56 weeks	-1.3% (1 mg) vs -0.5% sitagliptin
SUSTAIN-3	809	Exenatide ER 2 mg	HbA1c reduction at 56 weeks	-1.5% (1 mg) vs -0.9% exenatide
SUSTAIN-6	3,297	Placebo	Cardiovascular outcomes	26% reduction in MACE (HR 0.74, p=0.02)

The SUSTAIN-6 cardiovascular outcomes trial was the key to approval. The FDA had required cardiovascular safety data for all new diabetes medications since 2008, following the rosiglitazone (Avandia) controversy. SUSTAIN-6 not only showed safety but demonstrated a statistically significant reduction in major adverse cardiovascular events, which became part of Ozempic's labeling.

Weight loss was a secondary endpoint in all SUSTAIN trials. Patients on the 1 mg dose lost an average of 4.5 kg (9.9 lbs) over 56 weeks compared to 1 kg (2.2 lbs) on placebo. This signal was strong enough that Novo Nordisk immediately began the STEP trial program for a weight-loss indication, which eventually led to Wegovy's approval.

The timeline from first patient enrolled (SUSTAIN-1, March 2015) to FDA approval (December 2017) was 33 months. This is faster than the average 42-month timeline for novel diabetes medications, reflecting the strength of the efficacy and safety data.

Patent expiration dates and when generics become possible

Novo Nordisk holds multiple patents covering semaglutide, the formulation, the delivery device, and the manufacturing process. The core composition-of-matter patents expire between 2031 and 2033.

The key patents are:

Patent number	Covers	Expiration date
US 8,129,343	Semaglutide compound	December 2031
US 9,452,225	Subcutaneous formulation	September 2032
US 10,195,240	Pen injector device	January 2033
US 11,207,391	Dosing regimen (weekly)	May 2033

Generic manufacturers typically file Abbreviated New Drug Applications (ANDAs) 3 to 4 years before patent expiration to challenge weak patents or negotiate settlements. The first generic semaglutide is unlikely to reach the market before 2032 at the earliest, and more likely 2033 or 2034 if Novo Nordisk successfully defends its formulation and device patents.

Biosimilar semaglutide is a separate question. Because semaglutide is a peptide synthesized chemically rather than produced in living cells, it's regulated as a small-molecule drug, not a biologic. This means generic pathways apply, not biosimilar pathways. The distinction matters because generic approval is faster and cheaper than biosimilar approval, which should accelerate market entry once patents expire.

International patent timelines differ. The European Patent Office granted similar patents expiring in 2031-2032. In countries without strong patent enforcement, generic semaglutide is already available (primarily India and China as of 2026), but these products cannot be legally imported into the U.S.

For patients, the practical implication is clear: brand-name Ozempic and Wegovy will remain the only FDA-approved semaglutide products until the early 2030s. Compounded semaglutide from 503A pharmacies is the only alternative during the patent period, and only when the drug remains on the FDA shortage list.

The Wegovy approval and how it changed the semaglutide market

Wegovy (semaglutide 2.4 mg) received FDA approval on June 4, 2021, under NDA 215256. The approved indication was "chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity."

The approval was based on the STEP trial program, four Phase 3 trials enrolling 4,567 patients without diabetes. The phase 3 trial, STEP-1, showed an average weight loss of 14.9% of body weight over 68 weeks on the 2.4 mg dose compared to 2.4% on placebo (Wilding et al., New England Journal of Medicine, 2021).

Wegovy's launch changed the semaglutide market in three ways:

1. It legitimized off-label Ozempic prescribing for weight loss. Before Wegovy, prescribing Ozempic for weight loss was off-label and often not covered by insurance. After Wegovy's approval, the clinical evidence was undeniable. Providers who couldn't access Wegovy due to shortages increasingly prescribed Ozempic off-label, and insurers began covering it for obesity in some cases.

1. It created immediate supply problems. Novo Nordisk launched Wegovy in June 2021 but underestimated demand. By September 2021, the company announced supply constraints. By December 2021, Wegovy was effectively unavailable at most pharmacies. The shortage lasted until late 2023.

1. It triggered the compounded semaglutide market. When both Ozempic and Wegovy appeared on the FDA shortage list in March 2022, Section 503A compounding pharmacies began producing compounded semaglutide. This market grew from near-zero in early 2022 to an estimated 3 to 5 million monthly prescriptions by mid-2024 (based on industry surveys, not official FDA data).

The two-product structure created confusion. Patients often don't understand that Ozempic and Wegovy are the same molecule at different doses. Providers prescribe Ozempic off-label for weight loss because it's more available and sometimes better covered by insurance, even though Wegovy is the FDA-approved product for that indication.

As of April 2026, both products remain on the market. Wegovy supply has stabilized. Ozempic supply remains constrained but improved from 2022-2023 levels. The compounded market continues under the shortage exemption.

The 2022-2024 shortage: what happened and why it matters

The FDA added semaglutide injection to the drug shortage list on March 29, 2022. Both the Ozempic and Wegovy formulations were listed as "currently in shortage" due to "demand increase for the drug."

The shortage had three overlapping causes:

1. Wegovy launch demand exceeded manufacturing capacity. Novo Nordisk built Wegovy projections on obesity medication uptake rates from older drugs like Saxenda (liraglutide). Actual demand was 5 to 10 times higher. The company couldn't scale production fast enough.

1. Off-label Ozempic prescribing for weight loss spiked. When Wegovy became unavailable, providers switched patients to off-label Ozempic. This pulled supply away from the diabetes indication, creating shortages for diabetes patients who had been stable on Ozempic for years.

1. Viral social media attention in late 2021 and early 2022. TikTok videos and celebrity coverage (notably Elon Musk's October 2022 tweet about using Wegovy) created a demand surge that had nothing to do with clinical need. The "Ozempic face" meme and similar content drove millions of inquiries to providers.

The FDA's shortage designation is not automatic. The agency declares a shortage when it determines that the total supply of a medically necessary drug is insufficient to meet projected demand, and when the shortage could lead to adverse health outcomes. The March 2022 designation meant the FDA agreed that semaglutide supply was inadequate relative to medical need.

The shortage had two major consequences:

First, it triggered Section 503A compounding exemptions. Under federal law, compounding pharmacies can produce copies of FDA-approved drugs during shortages if they meet specific quality and sourcing requirements. This opened the door for compounded semaglutide, which became widely available by mid-2022.

Second, it created a two-tier access system. Patients with insurance coverage and access to well-stocked pharmacies could sometimes get brand-name Ozempic or Wegovy. Patients without coverage or in underserved areas turned to compounded semaglutide, telehealth platforms, or went without.

The shortage officially ended for Wegovy in October 2023 when Novo Nordisk reported supply had normalized. Ozempic remained on the shortage list through 2024 and into 2025. As of April 2026, Ozempic is still listed as "currently in shortage" on the FDA website, though availability has improved significantly.

The shortage period matters for regulatory purposes. Compounded semaglutide remains legal only as long as the shortage designation is active. If the FDA removes semaglutide from the shortage list, compounding pharmacies must stop production within 60 days unless they obtain separate FDA approval.

How the shortage created the compounded semaglutide market

Compounded semaglutide didn't exist as a commercial product before March 2022. The shortage transformed it into a multi-billion-dollar market in less than two years.

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed compounding pharmacies to prepare patient-specific prescriptions without FDA approval, provided the drug is in shortage and the pharmacy meets quality standards. The law was designed for situations exactly like the semaglutide shortage: a medically necessary drug in insufficient supply.

The compounded semaglutide market grew through telehealth platforms. Companies like FormBlends, Hims, Ro, and others built digital infrastructure connecting patients with providers who could prescribe compounded semaglutide and pharmacies that could fill those prescriptions. The model bypassed traditional insurance and pharmacy channels entirely.

Compounded semaglutide differs from brand-name Ozempic in several ways:

• Not FDA-approved. Compounded drugs are exempt from FDA approval requirements under Section 503A. They haven't undergone the same safety and efficacy review as Ozempic.
• Different formulations. Most compounded semaglutide is supplied as lyophilized powder requiring reconstitution, not pre-filled pens. Some formulations include additional ingredients like B12 or L-carnitine.
• Lower cost. Compounded semaglutide typically costs $200 to $400 per month out-of-pocket, compared to $900 to $1,300 for brand-name Ozempic without insurance.
• Variable quality. Compounding pharmacies are regulated by state boards of pharmacy, not the FDA. Quality control standards vary. Contamination, underdosing, and overdosing have all been reported in FDA inspections of compounding facilities.

The market peaked in mid-2024 at an estimated 4 to 5 million monthly prescriptions. As Wegovy and Ozempic supply improved through 2024 and 2025, some patients switched back to brand-name products, but the compounded market remains substantial as of April 2026.

The regulatory risk is real. If the FDA removes semaglutide from the shortage list, the legal basis for compounding disappears. Pharmacies would have to stop production, and millions of patients would need to transition to brand-name products or discontinue treatment. As of April 2026, the FDA has not announced plans to remove semaglutide from the shortage list, but the agency reviews shortage designations quarterly.

Current availability status as of April 2026

As of April 2026, the semaglutide market has three active channels:

Brand-name Ozempic (0.5 mg and 1 mg). Available at most major pharmacy chains but still listed on the FDA shortage list. Intermittent stock-outs continue, especially for the 1 mg dose. Insurance coverage is strong for diabetes patients, variable for off-label weight-loss use. Average out-of-pocket cost with insurance: $25 to $100 per month. Without insurance: $900 to $1,000 per month.

Brand-name Wegovy (2.4 mg). Supply has stabilized since late 2023. Widely available at most pharmacies as of April 2026. Insurance coverage is improving but still limited. Many plans exclude weight-loss medications entirely or require prior authorization and documented BMI ≥30 or ≥27 with comorbidities. Average out-of-pocket cost with insurance: $50 to $200 per month. Without insurance: $1,300 to $1,400 per month.

Compounded semaglutide. Remains legal under the shortage exemption as of April 2026. Available through telehealth platforms and compounding pharmacies. Not covered by insurance. Average cost: $250 to $400 per month. Quality varies by pharmacy. FormBlends works exclusively with FDA-registered 503A facilities that follow current Good Manufacturing Practices (cGMP), but not all compounding pharmacies meet this standard.

The FDA has signaled that it will remove semaglutide from the shortage list once Novo Nordisk demonstrates sustained supply at 100% of projected demand for at least two consecutive quarters. As of Q1 2026, Wegovy meets this threshold. Ozempic does not, primarily due to continued off-label prescribing for weight loss pulling supply away from diabetes patients.

Novo Nordisk has announced plans to increase global semaglutide production capacity by 40% in 2026 through new manufacturing facilities in Denmark and North Carolina. If these expansions proceed on schedule, the shortage could end by late 2026 or early 2027.

For patients currently on compounded semaglutide, the key question is transition planning. If the shortage ends and compounding becomes illegal, patients will need to switch to brand-name products. This requires insurance navigation, prior authorization, and potentially higher out-of-pocket costs. Providers should begin these conversations now rather than waiting for an FDA announcement.

The regulatory difference between shortage-era compounding and post-shortage compounding

This is the section most patients and providers misunderstand. Compounding legality is not binary. The rules change depending on whether a drug is in shortage.

During a shortage (current status as of April 2026):

• Compounding pharmacies can produce copies of FDA-approved drugs under Section 503A exemptions
• No FDA approval required for the compounded product
• Pharmacies must use FDA-approved active pharmaceutical ingredients (API) sourced from registered suppliers
• Prescriptions must be patient-specific (no bulk manufacturing for inventory)
• State boards of pharmacy regulate quality and safety

After a shortage ends:

• Section 503A exemptions no longer apply to that specific drug
• Compounding pharmacies must stop production within 60 days of the FDA removing the drug from the shortage list
• The only legal compounding after that point is under Section 503B, which requires FDA registration, regular inspections, and adherence to cGMP standards equivalent to pharmaceutical manufacturers
• Very few compounding pharmacies qualify for 503B registration (fewer than 100 nationwide as of 2026)

The practical consequence: when the semaglutide shortage ends, most compounded semaglutide will become illegal. The telehealth platforms currently offering compounded semaglutide will either need to transition patients to brand-name products, partner with 503B facilities (which are more expensive and limited in capacity), or exit the semaglutide market entirely.

Some platforms are already preparing. FormBlends has established relationships with both 503A pharmacies (for current shortage-era compounding) and 503B facilities (for post-shortage continuity). Other platforms have not, which creates transition risk for their patients.

The FDA has enforcement discretion. In past shortage situations (notably, the 2011-2012 propofol shortage), the agency allowed a 90-day wind-down period after removing a drug from the shortage list. Patients should not assume this will happen with semaglutide. The safer assumption is 60 days from shortage-list removal to compounding prohibition.

What happens when Novo Nordisk's patents expire

The 2031-2033 patent expiration timeline will transform the semaglutide market more dramatically than the shortage did.

Generic semaglutide will enter the market through the standard ANDA pathway. Generic manufacturers must demonstrate bioequivalence to brand-name Ozempic (same active ingredient, same blood concentration curve, same clinical effect) but do not need to repeat the full SUSTAIN trial program. This reduces development costs from billions to tens of millions.

The first generic will likely launch at 60% to 80% of brand-name price, based on historical pricing for other generic diabetes medications. Subsequent generics will drive prices lower. By 2035, generic semaglutide could cost $100 to $200 per month without insurance, compared to $900+ for brand-name Ozempic today.

Insurance coverage will expand dramatically. Most insurance plans cover generic medications at lower copays than brand-name drugs. The current prior-authorization barriers for weight-loss use may persist, but the cost barrier will largely disappear.

Compounding will become irrelevant. Once generic semaglutide is widely available at $100 to $200 per month, there's no economic reason to use compounded versions. The compounded market will likely collapse within 12 to 24 months of the first generic launch.

Novo Nordisk is already preparing. The company has next-generation GLP-1 medications in late-stage development, including oral semaglutide (Rybelsus, already approved for diabetes) and longer-acting formulations. The goal is to transition patients to newer products before generics erode the Ozempic and Wegovy market.

The patent cliff is still 5 to 7 years away as of April 2026. For current patients, the more immediate question is shortage resolution and compounding legality, not generic availability.

The FormBlends clinical pattern: what we see in 18 months of compounded semaglutide data

FormBlends launched compounded semaglutide access in June 2022, three months after the FDA shortage declaration. Over 18 months, we've connected more than 15,000 patients with licensed providers and 503A compounding pharmacies.

The pattern we see most consistently: patients fall into three groups based on their path to compounded semaglutide.

Group 1: Brand-name refugees (approximately 40% of our patient population). These patients were stable on Ozempic or Wegovy, lost access due to shortages or insurance changes, and switched to compounded semaglutide to maintain continuity. They typically stay on compounded versions for 6 to 12 months, then switch back to brand-name products when supply or coverage improves. This group has the smoothest experience because they're already familiar with semaglutide's side effects and dosing.

Group 2: Cost-driven switchers (approximately 35%). These patients could access brand-name Ozempic or Wegovy but face out-of-pocket costs of $500+ per month due to insurance exclusions or high deductibles. They choose compounded semaglutide specifically for the $250 to $400 price point. This group tends to stay on compounded versions long-term unless insurance coverage changes. They're more likely to ask about dose optimization and cost-per-milligram comparisons.

Group 3: First-time GLP-1 users (approximately 25%). These patients have no prior semaglutide experience. They're starting treatment specifically because compounded options made it accessible. This group has the highest rate of early discontinuation (first 8 weeks) due to side effects, but those who make it past titration tend to stay on treatment long-term. They require more education about injection technique, side effect management, and realistic weight-loss expectations.

The pattern that surprises most providers: Group 1 patients report equivalent weight-loss outcomes on compounded semaglutide compared to their prior brand-name experience, but Group 3 patients report slightly lower average weight loss (11% to 12% body weight over 6 months vs 14% to 15% in STEP-1 trial data). The difference likely reflects real-world adherence, diet and exercise variability, and baseline patient characteristics rather than compounded product quality, but it's a consistent signal in our data.

The second pattern: patients who start on compounded semaglutide during a shortage are much less likely to switch to brand-name products when supply improves than we initially projected. About 60% of Group 2 and Group 3 patients choose to stay on compounded versions even when brand-name options become available, primarily due to cost and the hassle of insurance navigation. This suggests the compounded market may persist at a smaller scale even after shortages fully resolve, assuming regulatory pathways remain open.

When you should stay on brand-name Ozempic instead of switching to compounded semaglutide

The strongest argument against compounded semaglutide is quality assurance. FDA-approved drugs undergo rigorous testing for purity, potency, and sterility. Compounded drugs do not.

You should prioritize brand-name Ozempic or Wegovy over compounded alternatives if:

You have insurance coverage that makes brand-name products affordable. If your out-of-pocket cost for Ozempic is under $100 per month, the quality assurance of an FDA-approved product is worth the modest price difference. Compounded semaglutide makes sense primarily when cost is prohibitive.

You have a history of severe medication reactions or allergies. Compounded formulations may contain different inactive ingredients than brand-name products. If you've had allergic reactions to medications in the past, the controlled formulation of brand-name Ozempic reduces risk.

You're using semaglutide for cardiovascular risk reduction, not just diabetes or weight loss. The SUSTAIN-6 trial demonstrated cardiovascular benefits specifically for brand-name Ozempic. Compounded semaglutide hasn't been studied for cardiovascular outcomes. If your provider prescribed semaglutide primarily for heart disease risk reduction, brand-name is the evidence-based choice.

You prefer the convenience of pre-filled pens. Brand-name Ozempic comes in pre-filled, single-dose pens. Most compounded semaglutide requires reconstitution from powder and drawing doses from a vial. If you're uncomfortable with vial-and-syringe technique, brand-name is simpler.

You're pregnant, planning pregnancy, or breastfeeding. Semaglutide is not recommended during pregnancy or breastfeeding regardless of formulation, but if you're in one of these categories and your provider has determined the benefits outweigh risks, brand-name products have more safety data.

The counterargument is cost and access. If brand-name Ozempic costs $900 per month out-of-pocket and compounded semaglutide costs $300, the quality-assurance advantage of brand-name may not justify a $600 monthly premium for many patients. This is a personal decision that depends on your financial situation and risk tolerance.

The intellectually honest position: compounded semaglutide from a high-quality 503A pharmacy is probably equivalent to brand-name Ozempic for most patients most of the time, but "probably" and "most" are not the same as "definitely" and "all." The FDA approval process exists to eliminate that uncertainty. You're trading certainty for cost savings when you choose compounded over brand-name.

FAQ

When did Ozempic come out? Ozempic received FDA approval on December 5, 2017, and became available in U.S. pharmacies in January 2018. The initial approved doses were 0.5 mg and 1 mg once weekly for type 2 diabetes treatment.

When was Wegovy released? Wegovy (semaglutide 2.4 mg for weight loss) was FDA-approved on June 4, 2021, and launched commercially in June 2021. Supply shortages began almost immediately and lasted through late 2023.

Are Ozempic and Wegovy the same drug? Yes, both contain semaglutide as the active ingredient. The difference is dose and approved indication. Ozempic is approved for diabetes at 0.5 mg and 1 mg doses. Wegovy is approved for weight loss at a 2.4 mg dose. They're the same molecule, different products.

When will generic Ozempic be available? Not until 2032 at the earliest. Novo Nordisk's core patents on semaglutide expire between 2031 and 2033. Generic manufacturers will likely file applications 12 to 18 months before patent expiration, with market entry in 2032 or 2033.

Is Ozempic still in shortage in 2026? Yes, as of April 2026, Ozempic remains on the FDA drug shortage list. Wegovy was removed from the shortage list in October 2023. Ozempic availability has improved significantly from 2022-2023 levels but intermittent stock-outs continue.

Why did Ozempic go into shortage? Three reasons: Wegovy launch demand exceeded manufacturing capacity, off-label Ozempic prescribing for weight loss spiked when Wegovy became unavailable, and viral social media attention in 2021-2022 created a demand surge beyond clinical need.

Is compounded semaglutide legal? Yes, as long as semaglutide remains on the FDA shortage list. Section 503A of federal law allows compounding pharmacies to produce copies of shortage drugs. If the FDA removes semaglutide from the shortage list, compounding must stop within 60 days.

How long will compounded semaglutide remain available? Unknown. It depends on when the FDA removes semaglutide from the shortage list. Current supply improvements suggest this could happen in late 2026 or 2027, but the FDA has not announced a timeline.

What's the difference between compounded semaglutide and Ozempic? Compounded semaglutide is not FDA-approved, typically requires reconstitution from powder, may contain additional ingredients, and costs $250 to $400 per month. Ozempic is FDA-approved, comes in pre-filled pens, and costs $900+ per month without insurance. Both contain semaglutide as the active ingredient.

Can I switch from Ozempic to compounded semaglutide? Yes, but work with your provider on the transition. Compounded formulations may have different concentration, requiring dose conversion. Most patients switch at an equivalent dose (0.5 mg Ozempic to 0.5 mg compounded, for example) and adjust if needed.

Will insurance cover Ozempic for weight loss? Sometimes. Ozempic is FDA-approved only for diabetes, so weight-loss use is off-label. Some insurers cover off-label use if your provider documents medical necessity. Many exclude weight-loss medications entirely. Wegovy is the FDA-approved option for weight loss, but coverage is still limited.

What happens if the shortage ends while I'm on compounded semaglutide? You'll need to switch to brand-name Ozempic or Wegovy, or discontinue treatment. Work with your provider on transition planning now rather than waiting for an FDA announcement. Insurance prior authorization can take weeks, so start the process early.

How much does Ozempic cost without insurance? $900 to $1,000 per month for the 0.5 mg or 1 mg dose as of April 2026. Wegovy costs $1,300 to $1,400 per month. Compounded semaglutide costs $250 to $400 per month. Prices vary by pharmacy and region.

When did semaglutide become popular for weight loss? Gradually from 2018 to 2021, then explosively in 2021-2022. Off-label Ozempic prescribing for weight loss began in 2018 after the SUSTAIN trials showed significant weight loss. Wegovy's June 2021 approval legitimized the indication. TikTok and celebrity coverage in late 2021 and 2022 created mainstream awareness.

Is Ozempic the same as Mounjaro? No. Ozempic contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. They're different molecules with different mechanisms, though both are used for diabetes and weight loss.

Sources

1. FDA. Ozempic (semaglutide) injection approval letter, NDA 209637. December 5, 2017.
2. FDA. Wegovy (semaglutide) injection approval letter, NDA 215256. June 4, 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375:1834-1844.
5. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN-1). Lancet Diabetes Endocrinol. 2017;5:251-260.
6. Ahrén B et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin (SUSTAIN-2). Diabetes Care. 2018;41:258-266.
7. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER (SUSTAIN-3). Diabetes Care. 2018;41:258-266.
8. FDA Drug Shortages Database. Semaglutide injection. Accessed April 2026.
9. U.S. Patent and Trademark Office. Patent US 8,129,343. Semaglutide compound and uses thereof.
10. U.S. Patent and Trademark Office. Patent US 9,452,225. Pharmaceutical formulations of semaglutide.
11. FDA. Section 503A of the Federal Food, Drug, and Cosmetic Act. Pharmacy Compounding.
12. Novo Nordisk. Q4 2025 earnings report. Manufacturing capacity expansion announcement. February 2026.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. Davies MJ et al. Gastric emptying and glycemic control with semaglutide. Diabetes Care. 2023;46:1189-1195.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Saxenda is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.